Author name: Rima Belfedhal

Uncategorized

Elementor #4160

For a generic pharmaceutical company, the Summary of Product Characteristics (SmPC) is not a creative writing exercise. It is a regulatory compliance task governed by the Principle of Concordance. The “Mirror Effect” is the industry standard approach: your generic SmPC must act as a mirror of the Reference Medicinal Product (the princeps) for all clinical and pharmacological data, while accurately reflecting the specific quality attributes of your own formulation. This guide breaks down the SmPC section by section, identifying what to copy, what to adapt, and where the data originates within your Common Technical Document (CTD).   Part 1: The Philosophy of the Mirror Why copy the Reference Product? Your generic marketing authorization is based on Article 10(1) of Directive 2001/83/EC. You are not proving safety and efficacy from scratch; you are proving

Digital Pharma

From Pyramids to Platforms: Imagining eCTD’s Evolution by 2050

For decades, the electronic Common Technical Document (eCTD) has been the backbone of regulatory submissions in the pharmaceutical industry. It brought standardization, global alignment, and structure in a field where precision is critical. But by 2050, this system, as remarkable and essential as it once was, will evolve into something far more fluid, intelligent, and integrated. The Pyramid as a Symbol of Excellence To imagine this shift, let’s take inspiration from one of the most admired human achievements: the pyramids of Egypt. The Egyptian pyramids are masterpieces of coordination, engineering, and vision. They symbolize structure, legacy, and human brilliance, timeless monuments that stood for thousands of years. They didn’t become “obsolete”; they became historical foundations that inspired generations of architects, scientists, and builders. Likewise, eCTD was the foundational architecture of 21st-century regulatory science. It brought: A common language to pharmaceutical submissions across the world, A digital framework to replace paper-based chaos, And a harmonized path toward regulatory approvals. But just as human needs changed after the era of pyramids, regulatory needs are now shifting 2050: A New Era of Regulatory Intelligence By 2050, the pharmaceutical world will no longer rely on “documents” submitted in sequences. Instead, regulatory submissions will be dynamic, data-driven processes, powered by real-time systems, artificial intelligence, and global connectivity. Here’s what that transformation could look like: 1. 📡 From Static Dossiers to Living Data Streams Today: You collect, format, and submit CTD modules. Tomorrow: Regulatory platforms are connected to your internal systems. When you change a batch site or update a clinical protocol, the system automatically syncs that change with Health Authorities—no need to repackage or resubmit. Think of it as a living submission, always up to date. 2. 🤖 AI Will Author Technical Documents Today: Experts write summaries for Modules 2 and 3 manually. Tomorrow: AI tools trained on global regulations and past submissions will generate high-quality, compliant CTD sections in seconds. Regulatory professionals will train, guide, and validate, rather than write from scratch. 3. 🌐 One Core Submission – Multiple Global Views A company submits its product data to a secure global cloud. Each country applies its own rules and validation checks automatically, using AI agents that understand local laws and languages. Instead of duplicating efforts, teams manage one structured product data source. 4. 🔐 Blockchain Ensures Trust By 2050, blockchain technology will play a central role in securing regulatory data. What is blockchain?Blockchain is a decentralized and tamper-proof system that records data in secure blocks, each linked to the previous one, making it almost impossible to alter or falsify. It’s like a digital ledger that can’t be erased or modified without leaving a trace. In regulatory affairs, this means: Every change—like a new manufacturer, updated certificate, or revised formulation—is automatically recorded and time-stamped. Health Authorities can instantly verify the history and authenticity of your data without repeated audits or resubmissions. Blockchain will bring built-in transparency and auditability, reducing manual oversight and boosting confidence. 5. 🧭 Regulatory Professionals as System Architects By 2050, the role of regulatory teams will shift: From document managers to data stewards. From submitting packages to orchestrating compliance across global platforms. From checking formats to shaping regulatory strategy through predictive simulations. Honoring the Legacy, Building the Future Just as the pyramids of ancient Egypt laid the foundations for centuries of architectural and scientific progress, eCTD laid the groundwork for a more intelligent regulatory future. It is not being “replaced”, it is evolving. The future of regulatory science is not about leaving structure behind, but about building on top of it, with tools that adapt, learn, and think. eCTD showed us what harmonization looks like. The next step is integration, automation, and intelligence. “As the regulatory world evolves toward 2050, RAPSKEY bridges the present and future of eCTD.” Learn more about it here. 

Digital Pharma

One Single Pharma Product Can Exceed 100 Data Fields!

Ever wonder what it really takes to bring one single pharmaceutical product to market? It’s far from simple. Behind every pill, every vial, every approved medicine, lies an intricate universe of data, often scattered across countless spreadsheets, endless email threads, forgotten local folders, daunting regulatory dossiers, and even individual team members’ memories. A single pharmaceutical product can demand the tracking and updating of more than 100 distinct pieces of information. From intricate technical specifications to critical regulatory events, from nuanced manufacturing changes to precise pricing data, every single detail matters. And in this high-stakes environment, a single missed update can trigger costly delays, lead to devastating non-compliance, or even result in the dreaded market withdrawal. 🕰️ The Analog Era: A Labyrinth of Paper and Confusion Before the advent of digital solutions, the management of this colossal amount of pharmaceutical product data was a truly daunting task. Imagine a world where critical information wasn’t just scattered across digital files, but literally hidden within mountains of physical paper. Regulatory submissions, manufacturing batch records, clinical trial results, and countless other vital documents resided in overflowing filing cabinets, dusty archives, and individual team members’ desks. Version management was a nightmare.Without a centralized digital system, tracking the latest approved artwork, the most current manufacturing process, or the updated regulatory approval date became an exercise in extreme diligence, and often, frustration. Different departments might be working with outdated versions of the same document, leading to costly errors, redundant efforts, and significant delays. The sheer volume of paper made auditing a Herculean effort, and ensuring everyone was on the same page felt like an impossible dream. This analog labyrinth was not just inefficient; it was a constant source of risk ! 📦 Let’s Unpack It: The Hidden Complexity of a 500 mg Oral Tablet (Fictional case)  You might think a simple 500 mg oral tablet is straightforward. Think again. Here’s just a glimpse (with fictional information for the sake of the demonstration) into the staggering amount of information teams must meticulously manage for that one product INN: Paracetamol Brand Name: Dolcetex Strength: 500 mg Dosage Form: Film-coated tablet Route of Administration: Oral Identification Packaging Regulatory CMC Clinical Use Pricing INN (International Nonproprietary Name): Paracetamol Brand Name: Dolcetex Strength: 500 mg Dosage Form: Film-coated tablet Route of Administration: Oral GTIN (Global Trade Item Number): 05412345000127 Internal SKU / Code: DOLC-500-ORAL-BL30 Therapeutic Area: Pain Management, Antipyretic Pharmacological Class: Analgesic / Antipyretic Primary Packaging: Type: PVC/Alu blister Tablet Count per Blister: 10 tablets Blister Type: Transparent PVC, aluminum foil backing Tamper-evident: Yes Desiccant: No Secondary Packaging: Format: Printed carton box Leaflet Included: Yes (Patient Information Leaflet – version 4.2) Carton Type: White cardboard, folded box Blister Configuration: 3 blisters per box (30 tablets total) Barcode on Box: Yes – EAN13 and QR code Dimensions (mm): 60 × 20 × 90 Language(s): French & Arabic Marketing Authorization (MA) Number: DZ-2023-1459 Approval Date (Initial MA): 12/09/2023 Registration Status: Approved (valid) Country of Registration: Algeria Marketing Authorization Holder (MAH): SmartPharma Algeria S.A.R.L. Initial MA Approval Date: 12/09/2023 Validity Period: 5 years Next Renewal Due Date: 12/09/2028 Regulatory Deadline for Submission: 12/03/2028 (6 months prior to expiry) Grace Period: 6 months post-expiry (until 12/03/2029) Renewal Status: Not yet submitted Planned Start of Preparation: February 2028 Responsible Team: Regulatory Affairs (Central & Local) Manufacturing Site: PharmaTech France, Le Mans GMP Status: Compliant, last inspection June 2024 Shelf Life: 36 months Storage Conditions: Store at 15–25°C Recent Batch Numbers: 23PT001, 23PT002 Primary Manufacturing Site: PharmaTech France, Le Mans Site Role: Drug Product Manufacturer (Compression, Coating, Packaging) GMP Status: Compliant – ANPP Inspection (June 2024) Site Code: PT-FR-001 Secondary Site: In progress (planned for Q1 2025) Packaging Site: Same as manufacturing (PharmaTech France) Indications: Relief of mild to moderate pain and reduction of fever. Dosage Regimen: 1 tablet (500 mg) every 6 hours; do not exceed 4 g/day. Method of Administration: Oral use; swallow whole with water. Contraindications: Severe liver impairment or known allergy to paracetamol. Special Warnings and Precautions: Risk of liver toxicity with overdose or prolonged use. Use in Special Populations: Safe during pregnancy if clearly needed; caution in liver disease. Pharmacodynamic Profile: Central analgesic and antipyretic action via prostaglandin inhibition. Overdose Information: May cause severe liver damage; antidote is N-acetylcysteine. Interactions: Increased risk of bleeding with long-term use alongside warfarin. List Price: 160 DZD (retail, including VAT). Ex-Factory Price: 110 DZD. Reimbursement Status: 80% reimbursed under national insurance. Reference Pricing: Based on average retail prices in Algeria and Morocco. Price Approval Authority: Ministry of Pharmaceutical Industry (DPM). Last Price Approval Date: 01/09/2023. Pricing Type: Controlled (public price fixed by authority). Currency Used: Algerian Dinar (DZD). Public Sector Tender Eligibility: Yes, listed on the reimbursement formulary. Commercial Launch Date: 15/10/2023. INN (International Nonproprietary Name): Paracetamol Brand Name: Dolcetex Strength: 500 mg Dosage Form: Film-coated tablet Route of Administration: Oral GTIN (Global Trade Item Number): 05412345000127 Internal SKU / Code: DOLC-500-ORAL-BL30 Therapeutic Area: Pain Management, Antipyretic Pharmacological Class: Analgesic / Antipyretic Primary Packaging: Type: PVC/Alu blister Tablet Count per Blister: 10 tablets Blister Type: Transparent PVC, aluminum foil backing Tamper-evident: Yes Desiccant: No Secondary Packaging: Format: Printed carton box Leaflet Included: Yes (Patient Information Leaflet – version 4.2) Carton Type: White cardboard, folded box Blister Configuration: 3 blisters per box (30 tablets total) Barcode on Box: Yes – EAN13 and QR code Dimensions (mm): 60 × 20 × 90 Language(s): French & Arabic Marketing Authorization (MA) Number: DZ-2023-1459 Approval Date (Initial MA): 12/09/2023 Registration Status: Approved (valid) Country of Registration: Algeria Marketing Authorization Holder (MAH): SmartPharma Algeria S.A.R.L. Initial MA Approval Date: 12/09/2023 Validity Period: 5 years Next Renewal Due Date: 12/09/2028 Regulatory Deadline for Submission: 12/03/2028 (6 months prior to expiry) Grace Period: 6 months post-expiry (until 12/03/2029) Renewal Status: Not yet submitted Planned Start of Preparation: February 2028 Responsible Team: Regulatory Affairs (Central & Local) Manufacturing Site: PharmaTech France, Le Mans GMP Status: Compliant, last inspection June 2024 Shelf Life: 36 months Storage Conditions: Store at 15–25°C Recent Batch Numbers: 23PT001, 23PT002 Primary

Basics 101

Smart Dose 101 – What You’ll Find Here and Why I Built It

In every regulatory submission, forecast, CAPA, or training plan, there are questions we hesitate to ask, often solved through trial, error, or late-night searches. Despite how capable we are, pharma professionals still work in silos, figuring things out alone. That’s where Smart Dose comes in. After 14 years in regulatory affairs, juggling shifting priorities and missing pieces, I’ve seen how often we rely on guesswork instead of structured support. I created this channel to demystify the pharmaceutical world ! Especially in regions like Algeria and across the MENA region, where information can be fragmented, outdated, or locked behind experience. Whether you’re in regulatory affairs, quality, market access, or still exploring where you fit in the industry, Smart Dose is for you. 💊 What is Smart Dose? Smart Dose is a content space for clarity, learning, and inspiration in pharma.It’s part of a broader mission I started with Smart Pill Solutions: to create digital tools and knowledge hubs that empower professionals and companies in our local pharma ecosystem. This channel is the voice behind that mission. 💬 Why I Built This? Because knowledge shouldn’t be hidden behind job titles or years of experience.Because I believe Algeria and MENA have a pharma story worth telling differently—digitally, smartly, and locally. What Will You Find Here ? To make your experience easier, Smart Dose is structured around 6 main categories: 📚 Pharma FAQs: Ask Smart Dose Ever wondered “Can I register this type of product in Algeria?” or “What’s the difference between CPP and FSC?” This section gives simple, no-fluff answers to real-world questions. 💻 Digital Pharma: Bytes & Molecules Pharma is going digital, and this space covers how.From eCTD systems to local tech trends, I’ll break down what’s happening and what it means for your work. 🧬 Deep Dives: Zoom In Sometimes you need more than a quick tip.This category is for long-form articles on regulatory strategy, submission planning, or key concepts explained in detail — always with real-world relevance. 🧍‍♀️ Uncommon Paths: Beyond the Bench Not all pharmacists work in hospitals or drugstores.Here, I’ll feature stories of professionals who pivoted — into tech, entrepreneurship, consulting, or policy. If you’ve ever felt “different,” this space is for you. 🎤 Interviews: 7 Questions With… Short, insightful conversations with senior leaders, bold thinkers, or young changemakers in pharma.Each interview gives a dose of insight, perspective, and inspiration. 🌍 Local Lens: Made in (Country) Whether you’re based in Algeria or work with the region, regulatory paths, timelines, and market conditions here matter. This section brings local insight with a professional edge. 🗣️ Multilingual by DesignBecause our region is rich in linguistic and cultural diversity, you’ll occasionally find content on Smart Dose written in English, French, or Arabic — depending on the audience, context, and topic.This choice reflects the way we actually work and communicate in the pharmaceutical field across Algeria and MENA: multilingual, adaptable, and open to all. 💡If you’d like to suggest a topic or share your own story, reach out via the “Contact Us” page. Smart Dose is just starting — and there’s space here for all of us. Follow the channel. Share what resonates. And let’s take smarter steps in pharma—together. Facebook Twitter LinkedIn

Scroll to Top